Aelis Farma discloses share buyback program details

Aelis Farma (Euronext Paris: AELIS), a clinical-stage biopharmaceutical company, has made available the description of its share buyback program, following authorization granted at the company's Annual General Meeting on June 3, 2026.

The buyback program was authorized under the 12th resolution of the Combined General Meeting, pursuant to Article L. 22-10-62 of the French Commercial Code. The Board of Directors was granted powers to implement the program, with the ability to subdelegate in accordance with applicable law.

In accordance with Article 241-3 of the General Regulation of the Autorité des Marchés Financiers (AMF), the program description is included in the company's Universal Registration Document, filed with the AMF on April 23, 2026, under reference number D.26-0284.

You May Also Be Interested In

• AMTD group discloses share repurchase totals, plans to expand buybacks
• Eurofins repurchases 160,000 shares in week of June 15-19
• EU approves Arrowhead's plozasiran for rare triglyceride disorder